FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022234082> ?p ?o ?g. }

• W2022234082 endingPage "327" @default.
• W2022234082 startingPage "323" @default.
• W2022234082 abstract "Purpose To evaluate the effect of tumor hypoxia on the expected level of cell killing by regimens of stereotactic ablative radiotherapy (SABR) and to determine the extent to which the negative effect of hypoxia could be prevented using a clinically available hypoxic cell radiosensitizer. Results and Discussion We have calculated the expected level of tumor cell killing from regimens of SABR, both with and without the assumption that 20% of the tumor cells are hypoxic, using the standard linear quadratic model and the universal survival curve modification. We compare the results obtained with our own clinical data for lung tumors of different sizes and with published data from other studies. We also have calculated the expected effect on cell survival of adding the hypoxic cell sensitizer etanidazole at clinically achievable drug concentrations. Modeling tumor cell killing with any of the currently used regimens of SABR produces results that are inconsistent with the majority of clinical findings if tumor hypoxia is not considered. However, with the assumption of tumor hypoxia, the expected level of cell killing is consistent with clinical data. For only some of the smallest tumors are the clinical data consistent with no tumor hypoxia, but there could be other reasons for the sensitivity of these tumors. The addition of etanidazole at clinically achievable tumor concentrations produces a large increase in the expected level of tumor cell killing from the large radiation doses used in SABR. Conclusions The presence of tumor hypoxia is a major negative factor in limiting the curability of tumors by SABR at radiation doses that are tolerable to surrounding normal tissues. However, this negative effect of hypoxia could be overcome by the addition of clinically tolerable doses of the hypoxic cell radiosensitizer etanidazole. To evaluate the effect of tumor hypoxia on the expected level of cell killing by regimens of stereotactic ablative radiotherapy (SABR) and to determine the extent to which the negative effect of hypoxia could be prevented using a clinically available hypoxic cell radiosensitizer. We have calculated the expected level of tumor cell killing from regimens of SABR, both with and without the assumption that 20% of the tumor cells are hypoxic, using the standard linear quadratic model and the universal survival curve modification. We compare the results obtained with our own clinical data for lung tumors of different sizes and with published data from other studies. We also have calculated the expected effect on cell survival of adding the hypoxic cell sensitizer etanidazole at clinically achievable drug concentrations. Modeling tumor cell killing with any of the currently used regimens of SABR produces results that are inconsistent with the majority of clinical findings if tumor hypoxia is not considered. However, with the assumption of tumor hypoxia, the expected level of cell killing is consistent with clinical data. For only some of the smallest tumors are the clinical data consistent with no tumor hypoxia, but there could be other reasons for the sensitivity of these tumors. The addition of etanidazole at clinically achievable tumor concentrations produces a large increase in the expected level of tumor cell killing from the large radiation doses used in SABR. The presence of tumor hypoxia is a major negative factor in limiting the curability of tumors by SABR at radiation doses that are tolerable to surrounding normal tissues. However, this negative effect of hypoxia could be overcome by the addition of clinically tolerable doses of the hypoxic cell radiosensitizer etanidazole." @default.
• W2022234082 created "2016-06-24" @default.
• W2022234082 creator A5016420174 @default.
• W2022234082 creator A5027216875 @default.
• W2022234082 creator A5039706503 @default.
• W2022234082 date "2010-10-01" @default.
• W2022234082 modified "2023-10-18" @default.
• W2022234082 title "Stereotactic Ablative Radiotherapy Should Be Combined With a Hypoxic Cell Radiosensitizer" @default.
• W2022234082 cites W1964481524 @default.
• W2022234082 cites W1969707978 @default.
• W2022234082 cites W1976563098 @default.
• W2022234082 cites W1995719697 @default.
• W2022234082 cites W2002641914 @default.
• W2022234082 cites W2002807490 @default.
• W2022234082 cites W2003669956 @default.
• W2022234082 cites W2011750204 @default.
• W2022234082 cites W2021006272 @default.
• W2022234082 cites W2022881840 @default.
• W2022234082 cites W2025251694 @default.
• W2022234082 cites W2031307716 @default.
• W2022234082 cites W2034004337 @default.
• W2022234082 cites W2043561789 @default.
• W2022234082 cites W2051021899 @default.
• W2022234082 cites W2064419187 @default.
• W2022234082 cites W2066814365 @default.
• W2022234082 cites W2069558776 @default.
• W2022234082 cites W2075396118 @default.
• W2022234082 cites W2077096883 @default.
• W2022234082 cites W2078919205 @default.
• W2022234082 cites W2081035348 @default.
• W2022234082 cites W2083336230 @default.
• W2022234082 cites W2087704303 @default.
• W2022234082 cites W2107814019 @default.
• W2022234082 cites W2110069491 @default.
• W2022234082 cites W2115538252 @default.
• W2022234082 cites W2119914737 @default.
• W2022234082 cites W2125257427 @default.
• W2022234082 cites W2128322858 @default.
• W2022234082 cites W2133164395 @default.
• W2022234082 cites W2136786497 @default.
• W2022234082 cites W2137189026 @default.
• W2022234082 cites W2153262899 @default.
• W2022234082 cites W2157259121 @default.
• W2022234082 cites W2157751183 @default.
• W2022234082 cites W2159746573 @default.
• W2022234082 cites W2167270572 @default.
• W2022234082 cites W2319463151 @default.
• W2022234082 cites W4244235364 @default.
• W2022234082 doi "https://doi.org/10.1016/j.ijrobp.2010.04.070" @default.
• W2022234082 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2939040" @default.
• W2022234082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20832663" @default.
• W2022234082 hasPublicationYear "2010" @default.
• W2022234082 type Work @default.
• W2022234082 sameAs 2022234082 @default.
• W2022234082 citedByCount "119" @default.
• W2022234082 countsByYear W20222340822012 @default.
• W2022234082 countsByYear W20222340822013 @default.
• W2022234082 countsByYear W20222340822014 @default.
• W2022234082 countsByYear W20222340822015 @default.
• W2022234082 countsByYear W20222340822016 @default.
• W2022234082 countsByYear W20222340822017 @default.
• W2022234082 countsByYear W20222340822018 @default.
• W2022234082 countsByYear W20222340822019 @default.
• W2022234082 countsByYear W20222340822020 @default.
• W2022234082 countsByYear W20222340822021 @default.
• W2022234082 countsByYear W20222340822022 @default.
• W2022234082 countsByYear W20222340822023 @default.
• W2022234082 crossrefType "journal-article" @default.
• W2022234082 hasAuthorship W2022234082A5016420174 @default.
• W2022234082 hasAuthorship W2022234082A5027216875 @default.
• W2022234082 hasAuthorship W2022234082A5039706503 @default.
• W2022234082 hasBestOaLocation W20222340822 @default.
• W2022234082 hasConcept C106159729 @default.
• W2022234082 hasConcept C126322002 @default.
• W2022234082 hasConcept C143998085 @default.
• W2022234082 hasConcept C1491633281 @default.
• W2022234082 hasConcept C162324750 @default.
• W2022234082 hasConcept C178790620 @default.
• W2022234082 hasConcept C185592680 @default.
• W2022234082 hasConcept C187625094 @default.
• W2022234082 hasConcept C19617505 @default.
• W2022234082 hasConcept C202751555 @default.
• W2022234082 hasConcept C2776428644 @default.
• W2022234082 hasConcept C2779081379 @default.
• W2022234082 hasConcept C2780387249 @default.
• W2022234082 hasConcept C2781305896 @default.
• W2022234082 hasConcept C502942594 @default.
• W2022234082 hasConcept C509974204 @default.
• W2022234082 hasConcept C540031477 @default.
• W2022234082 hasConcept C54355233 @default.
• W2022234082 hasConcept C55493867 @default.
• W2022234082 hasConcept C71924100 @default.
• W2022234082 hasConcept C7836513 @default.
• W2022234082 hasConcept C85393063 @default.
• W2022234082 hasConcept C86803240 @default.
• W2022234082 hasConcept C91602232 @default.
• W2022234082 hasConceptScore W2022234082C106159729 @default.
• W2022234082 hasConceptScore W2022234082C126322002 @default.

• next